SCENAR Technology and SCENAR Devices

02-026
Electric Device For Bisphosphonate-Induced Osteonecrosis
Boris Zaidiner1, Ilia Baranovsky2, Darya Leontyeva3, Irene
Petrenko2
1Regional Cancer Hospital, Out-patient Care, Rostov-on-
Don, Russia, 2Medical Unit, Laboratory of Immunology,
Rostov-on-Don, Russia, 3Research Cancer Center, Laboratory
of Biophysics, Rostov-on-Don, Russia, 4Medical Unit,
Laboratory of Endocrinology, Rostov-on-Don, Russia
Objectives: Osteonecrosis of the jaw (ONJ) is serious
adverse event in patients (pts) who administer bisphosphonates
for metastatic bone disease. Its management
outcome remains poor. To improve results of conventional
treatment we’ve used electric therapy device (“SCENAR”,
US Patent N 5257623) which was tested in some fields of
supportive care. This is attempt to show our experience in
SCENAR-technology usage for ONJ.
Methods: In preliminary trial 28 pts with bisphosphonaterelated
ONJ (mean age 59,2 years, range 36–81 years) were
enrolled; nosologic forms: breast cancer 9 pts, prostate
cancer 7 pts, lung cancer 6 pts, multiple myeloma 3 pts,
renal cell cancer 2 pts, far-advanced malignancy without
verified primary site - 1 patient. Clinical picture was
presented with pain (at rest & jaw movement), swelling,
exposed bone; suppuration was noted in 3 pts. Dental
surgery prior to bisphosphonate therapy was in almost all
pts. After signing the informed consent every patient 15
SCENAR-procedures was performed in addition to conventional
supportive care. During these procedures various
cutaneous and mucosal areas were treated, their choice was
based upon patient’s complaints, their technique was
described earlier.
Results: In 17 pts (60,7%) positive results were achieved.
They felt better, had partial pain relief (the relief ratings on
VAS were significantly improved). In 5 of 19 pts with
exposed oral maxillofacial bone the lesions had tendency to
heal; in 2 of these 5 pts radiographic changes have become
less obvious.
Conclusions: In our study group adding SCENAR to
standard therapy appeared to result in more promising
outcome then available literature data were presented.
Further research is necessary to establish its exact position
in multimodal approach for bisphosphonate-related ONJ